John J. Renger

9.2k citations

127 papers · 6.1k indexed · 1 hit paper · h-index 45

Cellular and Molecular Neuroscience top 0.5%
Cognitive Neuroscience top 0.5%
Molecular Biology top 5%
Endocrine and Autonomic Systems top 0.2%
Experimental and Cognitive Psychology top 0.5%

Co-authors: Christopher J. Winrow Victor N. Uebele Paul J. Coleman Anthony L. Gotter Bryan A. Stewart H. L. Atwood Jing W. Wang Chunfu Wu
Topics: Sleep and Wakefulness Research (58 papers)Circadian rhythm and melatonin (42 papers)Sleep and related disorders (38 papers)
Cited by: Endocrine and Autonomic Systems Cellular and Molecular Neuroscience Cognitive Neuroscience
Journals: Proceedings of the National Academy of Sciences The Lancet Journal of Clinical Investigation
Partner nations: United States Japan France

In The Last Decade

John J. Renger

126 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved stability of Drosophila larval neuromuscular preparations in haemolymph-like physiological solutions

1994 686 citations John J. Renger et al. profile →

Peers

Countries citing papers authored by John J. Renger

Since Specialization

Citations

This map shows the geographic impact of John J. Renger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Renger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Renger more than expected).

Fields of papers citing papers by John J. Renger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Renger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Renger. The network helps show where John J. Renger may publish in the future.

Co-authorship network of co-authors of John J. Renger

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Renger. A scholar is included among the top collaborators of John J. Renger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Renger. John J. Renger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PET imaging of M4 muscarinic acetylcholine receptors in rhesus macaques using [¹¹C]MK-6884: Quantification with kinetic modeling and receptor occupancy by CVL-231 (emraclidine), a novel positive allosteric modulator 2024 ·Journal of Cerebral Blood Flow & Metabolism ·Vasily Belov,Nicolas J. Guehl,Sridhar Duvvuri,(unknown),Sung‐Hyun Moon,Maëva Dhaynaut,(unknown),(unknown),Peter A. Rice,Daniel Yokell,John J. Renger,Georges El Fakhri,Marc D. Normandin	4
2	Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial 2022 ·The Lancet ·John H. Krystal,John M. Kane,Christoph U. Correll,David P. Walling,Matthew Leoni,Sridhar Duvvuri,(unknown),Ih Chang,(unknown),(unknown),(unknown),Pamela Perry,Raymond Sanchez,John J. Renger	77
3	Orexin receptors in GtoPdb v.2021.3 2021 ·IUPHAR/BPS Guide to Pharmacology CITE ·Paul J. Coleman,Luı́s de Lecea,Anthony L. Gotter,Jim J. Hagan,Daniël Hoyer,Thomas S. Kilduff,Jyrki P. Kukkonen,Rod A. Porter,John J. Renger,Jerome M. Siegel,(unknown),Neil Upton,Christopher J. Winrow	3
4	Orexin signaling during social defeat stress influences subsequent social interaction behaviour and recognition memory 2018 ·Behavioural Brain Research ·Darrell Eacret,Laura A. Grafe,(unknown),Anthony L. Gotter,John J. Renger,Christopher J. Winrow,Seema Bhatnagar	27
5	Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain 2016 ·Journal of Neurogenetics ·Terrence P. McDonald,(unknown),Raul Sanoja,Anthony L. Gotter,Scott D. Kuduk,Paul J. Coleman,Karen Smith,Christopher J. Winrow,John J. Renger	4
6	Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements 2015 ·Bioorganic & Medicinal Chemistry Letters ·Anthony J. Roecker,Swati P. Mercer,Jeffrey M. Bergman,Kevin F. Gilbert,Scott D. Kuduk,C. Meacham Harrell,Susan L. Garson,Steven V. Fox,Anthony L. Gotter,Pamela L. Tannenbaum,Thomayant Prueksaritanont,Tamara D. Cabalu,Donghui Cui,Wei Lemaire,Christopher J. Winrow,John J. Renger,Paul J. Coleman	14
7	Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant 2014 ·Bioorganic & Medicinal Chemistry Letters ·Scott D. Kuduk,(unknown),Christina N. Di Marco,Joseph G. Bruno,(unknown),Julie A. O’Brien,Tamara D. Cabalu,Joanne Stevens,(unknown),Pamela L. Tannenbaum,Anthony L. Gotter,Christopher J. Winrow,John J. Renger,Paul J. Coleman	7
8	Differential sleep-promoting effects of dual orexin receptor antagonists and GABAAreceptor modulators 2014 ·BMC Neuroscience ·Anthony L. Gotter,Susan L. Garson,Joanne Stevens,(unknown),Steven V. Fox,Pamela L. Tannenbaum,Lihang Yao,Scott D. Kuduk,Terrence McDonald,Jason M. Uslaner,Spencer J. Tye,Paul J. Coleman,Christopher J. Winrow,John J. Renger	40
9	Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs 2014 ·Frontiers in Behavioral Neuroscience ·Pamela L. Tannenbaum,Joanne Stevens,(unknown),Alan T. Savitz,Susan L. Garson,Steven V. Fox,Paul J. Coleman,Scott D. Kuduk,Anthony L. Gotter,Michael J. Marino,Spencer J. Tye,Jason M. Uslaner,Christopher J. Winrow,John J. Renger	32
10	Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain 2013 ·Neurodegenerative Diseases ·Guoxin Wu,Ronald Miller,Brett Connolly,Jacob Marcus,John J. Renger,Mary J. Savage	28
11	Orexin receptors as therapeutic drug targets 2012 ·Progress in brain research ·Anthony L. Gotter,Anthony J. Roecker,Richard Hargreaves,Paul J. Coleman,Christopher J. Winrow,John J. Renger	79
12	The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey 2012 ·Neuropharmacology ·Sean M. Smith,Jason M. Uslaner,Christopher D. Cox,Sarah L. Huszar,Christopher E. Cannon,Joshua D. Vardigan,Donnie Eddins,Dawn Toolan,Monika Kandebo,Lihang Yao,Izzat T. Raheem,John D. Schreier,Michael J. Breslin,Paul J. Coleman,John J. Renger	70
13	Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat 2012 ·Psychopharmacology ·Marsida Kallupi,Giordano de Guglielmo,Nazzareno Cannella,(unknown),Girolamo Calò,Remo Guerrini,Massimo Ubaldi,John J. Renger,Victor N. Uebele,Roberto Ciccocioppo	34
14	Nerve Terminal Nicotinic Acetylcholine Receptors Initiate Quantal GABA Release from Perisomatic Interneurons by Activating Axonal T-Type (Ca_v3) Ca²⁺Channels and Ca²⁺Release from Stores 2011 ·Journal of Neuroscience ·Ai‐Hui Tang,Miranda A. Karson,Daniel A. Nagode,J. Michael McIntosh,Victor N. Uebele,John J. Renger,Matthias Klugmann,Teresa A. Milner,Bradley E. Alger	78
15	Identification of Causal Genes, Networks, and Transcriptional Regulators of REM Sleep and Wake 2011 ·SLEEP ·Joshua Millstein,Christopher J. Winrow,Andrew Kasarskis,(unknown),(unknown),Keith C. Summa,(unknown),Bin Zhang,Martha Hotz Vitaterna,Eric E. Schadt,John J. Renger,Fred W. Turek	16
16	Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey Y. Melamed,(unknown),Nathan R. Kett,Anthony L. Gotter,Victor N. Uebele,Duane R. Reiss,Cindra Condra,Christine Fandozzi,Laura S. Lubbers,Blake A. Rowe,Georgia B. McGaughey,Martin Hénault,Rino Stocco,John J. Renger,George D. Hartman,Mark T. Bilodeau,B. Wesley Trotter	21
17	Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist 2009 ·Journal of Cardiovascular Pharmacology ·Joseph J. Lynch,Christopher P. Regan,Gary L. Stump,Pamela L. Tannenbaum,Joanne Stevens,Ashleigh Bone,(unknown),(unknown),(unknown),Norihiro Takenaga,Shigeru Tokita,Tsuyoshi Nagase,Nagaaki Sato,John J. Renger	8
18	Uncovering the Genetic Landscape for Multiple Sleep-Wake Traits 2009 ·PLoS ONE ·Christopher J. Winrow,(unknown),Andrew Kasarskis,Joshua Millstein,Aaron D. Laposky,He S. Yang,(unknown),(unknown),(unknown),Daniel Radzicki,Fabian Preuss,Eric E. Schadt,Kazuhiro Shimomura,Martha Hotz Vitaterna,Chunsheng Zhang,Kenneth S. Koblan,John J. Renger,Fred W. Turek	30
19	Evaluation of Automated and Semi-Automated Scoring of Polysomnographic Recordings from a Clinical Trial Using Zolpidem in the Treatment of Insomnia 2007 ·SLEEP ·Vladimir Svetnik,Junshui Ma,Keith A. Soper,Scott M. Doran,John J. Renger,Steve Deacon,Ken S. Koblan	45
20	Regulation of Gene Expression by Lithium and Depletion of Inositol in Slices of Adult Rat Cortex 2005 ·Neuron ·Philip E. Brandish,(unknown),Daniel Holder,Paul Hodor,(unknown),Robert Kleinhanz,(unknown),(unknown),Sven Duenwald,Mark L Parrish,Na Sang,Yuan Liu,Robert L. Phillips,John J. Renger,Sethu Sankaranarayanan,Adam J. Simon,Edward M. Scolnick	69

About John J. Renger

John J. Renger is a scholar working on Endocrine and Autonomic Systems, Cognitive Neuroscience and Experimental and Cognitive Psychology, having authored 127 papers that have together received 6.1k indexed citations. Recurring topics across this work include Sleep and Wakefulness Research (58 papers), Circadian rhythm and melatonin (42 papers) and Sleep and related disorders (38 papers). The work is most often cited by research in Endocrine and Autonomic Systems (1.6k citations), Cellular and Molecular Neuroscience (2.5k citations) and Cognitive Neuroscience (2.4k citations). John J. Renger has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Christopher J. Winrow, Victor N. Uebele, Paul J. Coleman, Anthony L. Gotter, Bryan A. Stewart, H. L. Atwood, Jing W. Wang, Chunfu Wu, Guosong Liu and Christophe Egles. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact